Response by Pasupathy et al to Letters Regarding Article, "early Use of N-acetylcysteine (NAC) with Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (The NACIAM Trial [N-Acetylcysteine in Acute Myocardial Infarction])"

Sivabaskari Pasupathy, Rosanna Tavella, John F. Beltrame

Research output: Contribution to journalLetterpeer-review

Abstract

We appreciate the correspondence concerning the NACIAM trial (N-acetylcysteine in Acute Myocardial Infarction),1 which focused on the study analytical methods and potential mechanisms contributing to the benefits of N-acetylcysteine (NAC)/nitroglycerin use in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Original languageEnglish
Pages (from-to)1424-1425
Number of pages2
JournalCirculation
Volume137
Issue number13
DOIs
Publication statusPublished - 27 Mar 2018
Externally publishedYes

Keywords

  • N-acetylcysteine
  • Primary percutaneous coronary intervention
  • Myocardial infarction

Cite this